Alignment Healthcare enters the final stretch before its July 30 earnings report with a striking divergence: the stock has surged 56% over the past month, yet virtually every senior insider has been selling into the move.
The insider activity is the standout story here. CEO and founder John Kao sold roughly 298,000 shares on June 10 alone — worth around $6.1 million at prices between $19.65 and $20.60. The Executive Vice Chairman, Joseph Konowiecki, has been selling 25,000 shares a week, with transactions on June 11, June 18, June 26, and again on July 1, bringing his total to 100,000 shares over the month at prices escalating from $21 to $24. The President and the Chief Medical Officer also sold in mid-June. Against a single small purchase of roughly $198,000 by a divisional president on June 2, net insider selling over the past 90 days tallies to nearly $27.6 million. The pattern is systematic, not opportunistic — a cadence of pre-planned sales being executed at successively higher prices as the stock has run.
Short positioning tells a more complicated story. At 13.1% of free float, short interest is elevated — and it has barely moved despite the 56% price surge. The 30-day change is a modest 2.2%, and the one-week reading is essentially flat at -0.3%. Bears have not covered. Yet the lending market is not tight: borrow availability runs at roughly 376% — meaning nearly four shares are available to borrow for every one currently lent out — and the cost to borrow is only 0.56%, up modestly from 0.44% six weeks ago. The ORTEX short score has eased slightly to 60.7 from a recent peak near 62.6, though it remains elevated. Taken together, a meaningful short base is in place, but there is no squeeze dynamic and no signal of urgency on either side of the trade.
Options positioning has shifted slightly more defensive as the rally extended. The put/call ratio moved up to 0.18, above its 20-day average of 0.15 and roughly 1.4 standard deviations elevated — not alarming, but worth noting given the stock's recent pace. The 52-week range for the PCR runs from 0.02 to 0.24, so the current level sits in the upper half without hitting extremes. Calls still dominate by a wide margin; this is a stock where options traders have overwhelmingly favored upside exposure over the past year, and that has not fundamentally changed.
The Street has been slow to reprice. The most recent analyst actions — Barclays cutting its target to $16 in late May while keeping an Equal Weight, and UBS nudging up to $22 — both look stale against a stock now trading at $24.05. JP Morgan carried an Overweight with a $26 target as of February, which at least brackets the current price. With the consensus buy rating and these targets, the analyst community appears caught between a bullish longer-term view on ALHC's Medicare Advantage positioning and a stock price that has moved faster than their models. The bull case centres on Stars funding advantages and improving gross profit per member as cohorts mature; bears point to payor data friction and a valuation — PE near 40x, PB above 14x — that has expanded sharply alongside the price. The 30-day change in the price-to-book multiple alone is nearly 6 turns. EPS momentum factor scores sit in the 89th percentile on both 30- and 90-day windows, supporting the bulls, while the short score rank in the 11th percentile reflects that shorts have not yet conceded the trade.
The last two earnings reactions were sharply divergent: a 7.9% gain on the day and a 42% five-day move after the June 4 print, against a 6.7% one-day drop and a 16% five-day decline after the April 30 release. With institutional buyers including BlackRock adding 4.6 million shares and Capital Research adding 4.0 million in the latest reported periods, the ownership picture remains constructive — but the combination of systematic insider selling at current levels, a short base that has not moved, and analyst targets mostly below or just at the current price makes the July 30 print the moment where these competing signals will need to resolve.
See the live data behind this article on ORTEX.
Open ALHC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
